US challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competition

US challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competition

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

Leave a Reply

Your email address will not be published. Required fields are marked *

Optimized by Optimole